ATM serine/threonine kinase

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

Retrieved on: 
Friday, July 16, 2021
Cancer treatments, Clinical medicine, Drugs, Breakthrough therapy, Orphan drugs, Cancer immunotherapy, Pembrolizumab, Lung cancer, Effector, Non-small-cell lung carcinoma, ATM serine/threonine kinase

This publication further validates the novel science on which eFFECTORs platform is built, said Steve Worland, Ph.D., president and CEO of eFFECTOR.

Key Points: 
  • This publication further validates the novel science on which eFFECTORs platform is built, said Steve Worland, Ph.D., president and CEO of eFFECTOR.
  • We are proud that our contributions have the potential to broaden the treatment landscape for those impacted by cancer.
  • Tomivosertib is being evaluated in KICKSTART, eFFECTORs randomized, double-blind, placebo-controlled Phase 2b study in non-small cell lung cancer (NSCLC) in combination with pembrolizumab.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, June 30, 2021
Tyrosine kinase receptors, Lung cancer, Branches of biology, ROS1, Non-small-cell lung carcinoma, Anaplastic lymphoma kinase, Clinical medicine, Epidermal growth factor receptor, ATM serine/threonine kinase, Targeted therapy, ALK inhibitor, Protein kinase inhibitor

The AmoyDx PLC Panel has received approval for four driver genes (EGFR, ALK, ROS1, and BRAF) for nine associated targeted therapies in NSCLC.

Key Points: 
  • The AmoyDx PLC Panel has received approval for four driver genes (EGFR, ALK, ROS1, and BRAF) for nine associated targeted therapies in NSCLC.
  • With its high sensitivity and short turnaround time, The AmoyDx PLC Panel is expected to be an important clinical diagnostic in guiding treatment opportunities for NSCLC patients.
  • We are pleased to collaborate with AmoyDx and PREMIA in obtaining approval of the AmoyDx PLC Panel in Japan.
  • Detection of EGFR gene mutations, ALK fusion gene, ROS1 fusion gene, and BRAF gene mutations in nucleic acids extracted from cancer tissue

Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 16, 2021
Technology, Science and technology, Clinical research, Deception, Placebo, Automated teller machine, Asynchronous Transfer Mode, ATM serine/threonine kinase, Articles

The Company expects to begin enrollment of up to 65 patients in the second quarter of 2021.

Key Points: 
  • The Company expects to begin enrollment of up to 65 patients in the second quarter of 2021.
  • In September 2020, Vaccinex reported topline data from its Phase 2, double-blind, placebo-controlled SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntingtons disease (HD).
  • Subsequent to the end of the fourth quarter, the Company raised $32 million in net proceeds through its existing open sale market agreement, or ATM.
  • Subsequent to the end of the fourth quarter 2020, the Company raised $32 million in net proceeds through its pre-existing ATM.

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Clinical medicine, Proteins, Oncology, Tumor suppressor genes, Hereditary cancers, P53, Cancer, ATM serine/threonine kinase, Carcinogenesis, Neoplasm, Breast cancer

Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy.

Key Points: 
  • Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy.
  • The p53 Y220C mutation is associated with many cancers, including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic, and ovarian cancers.
  • PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

United States Head & Neck Cancers Market Report: Epidemiology, Valuations And Forecast, Drugs Sales and Competitive Landscape 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 8, 2021
Health, Oncology, RTT, Otorhinolaryngology, Head and neck cancer, Cancer, ATM serine/threonine kinase

The "US Head & Neck Cancers Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Head & Neck Cancers Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US Head & Neck Cancers Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Head & Neck Cancers pipeline products, Head & Neck Cancers epidemiology, Head & Neck Cancers market valuations and forecast, Head & Neck Cancers drugs sales and competitive landscape in the US.
  • Head & Neck Cancers pipeline: Find out the products in clinical trials for the treatment of Head & Neck Cancers by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Head & Neck Cancers epidemiology: Find out the number of patients diagnosed (prevalence) with Head & Neck Cancers in the US
    Head & Neck Cancers drugs: Identify key products marketed and prescribed for Head & Neck Cancers in the US, including trade name, molecule name, and company
    Head & Neck Cancers drugs sales: Find out the sales revenues of Head & Neck Cancers drugs in the US
    Head & Neck Cancers market valuations: Find out the market size for Head & Neck Cancers drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Head & Neck Cancers drugs market share: Find out the market shares for key Head & Neck Cancers drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Head & Neck Cancers products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005471/en/

New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations

Retrieved on: 
Friday, December 11, 2020
Branches of biology, Hereditary cancers, Health, Breast cancer, Oncology, Cancer syndrome, ATM serine/threonine kinase, Cancer, BRCA mutation, BRCA1

The new Myriad study highlights how riskScore, a proprietary tool used to evaluate a womans risk of developing breast cancer, can accurately provide breast cancer risk information into a personalized assessment model for women carrying a pathogenic variant (PV) in the ATM gene.

Key Points: 
  • The new Myriad study highlights how riskScore, a proprietary tool used to evaluate a womans risk of developing breast cancer, can accurately provide breast cancer risk information into a personalized assessment model for women carrying a pathogenic variant (PV) in the ATM gene.
  • This new study will enable a highly personalized risk calculation for patients who carry mutations in the ATM gene, said Nicole Lambert, president of Myriad Genetic Laboratories.
  • riskScore is performed in conjunction with Myriads myRisk Hereditary Cancer test, where myRisk identifies people who carry specific cancer-linked genetic mutations.
  • This study highlights the development of a comprehensive breast cancer risk model for ATM PV carriers incorporating an 86-variant PRS, along with family history and clinical information captured by Tyrer-Cuzick (a tool used to calculate the risk of breast cancer).

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Retrieved on: 
Tuesday, October 13, 2020
Branches of biology, Clinical medicine, Health, Proteins, Oncology, RTT, Tumor suppressor genes, P53, Programmed cell death, Cancer, ATM serine/threonine kinase, Ovarian cancer

The p53 Y220C mutation is associated with many cancers including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic and ovarian cancers.

Key Points: 
  • The p53 Y220C mutation is associated with many cancers including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic and ovarian cancers.
  • Fast Track designation reflects the recognition by the FDA that PC14586 has the potential to address a significant unmet medical need for advanced cancer patients with a p53 Y220C mutation, said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.
  • Phase 2 is an open-label study designed to assess anti-tumor efficacy and safety in patients with solid tumors that have a p53 Y220C mutation.
  • PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

US Head & Neck Cancers Market and Competitive Landscape 2016-2025 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 15, 2020
Health, Oncology, RTT, Health effects of tobacco, Otorhinolaryngology, Head and neck cancer, Cancer, ATM serine/threonine kinase

The "US Head & Neck Cancers Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Head & Neck Cancers Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Head & Neck Cancers Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Head & Neck Cancers pipeline products, Head & Neck Cancers epidemiology, Head & Neck Cancers market valuations and forecast, Head & Neck Cancers drugs sales and competitive landscape in the US.
  • Head & Neck Cancers pipeline: Find out the products in clinical trials for the treatment of Head & Neck Cancers by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Head & Neck Cancers epidemiology: Find out the number of patients diagnosed (prevalence) with Head & Neck Cancers in the US
    Head & Neck Cancers drugs: Identify key products marketed and prescribed for Head & Neck Cancers in the US, including trade name, molecule name, and company
    Head & Neck Cancers drugs sales: Find out the sales revenues of Head & Neck Cancers drugs in the US
    Head & Neck Cancers market valuations: Find out the market size for Head & Neck Cancers drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Head & Neck Cancers drugs market share: Find out the market shares for key Head & Neck Cancers drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Head & Neck Cancers products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005678/en/

SkinCeuticals Announces the Launch of Tripeptide-R Neck Repair

Retrieved on: 
Monday, August 17, 2020
Peptides, Branches of biology, Tripeptide, Otorhinolaryngology, Peptide, ATM serine/threonine kinase, Ageing

NEW YORK, Aug.17, 2020 /PRNewswire/ -- SkinCeuticals, a leader in advanced skincare technology, announces the launch of Tripeptide-R Neck Repair.

Key Points: 
  • NEW YORK, Aug.17, 2020 /PRNewswire/ -- SkinCeuticals, a leader in advanced skincare technology, announces the launch of Tripeptide-R Neck Repair.
  • SkinCeuticals Tripeptide-R Neck Repair is a fortifying, high-performance treatment that targets the neck for early to advanced signs of aging.
  • SkinCeuticals Tripeptide-R Neck Repair is specifically formulated to address these concerns with a tri-functional corrective technology made up of three key ingredients.
  • The Tripeptide-R Neck Repair's tri-functional corrective technology works strategically to target loose skin, horizontal neck lines and crepiness to combat signs of neck aging.

Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor

Retrieved on: 
Monday, June 22, 2020
Cancer treatments, Cancer, Clinical medicine, Antineoplastic drugs, Non-small-cell lung carcinoma, Pembrolizumab, Ras GTPase, Lung cancer, PTPN11, ATM serine/threonine kinase

Pembrolizumab is an approved standard of care for the treatment of NSCLC, including lung cancers harboring RAS pathway mutations.

Key Points: 
  • Pembrolizumab is an approved standard of care for the treatment of NSCLC, including lung cancers harboring RAS pathway mutations.
  • We have previously shown, in a preliminary report, that RMC-4630 (SAR442720) has activity against NSCLC bearing mutant RAS.
  • The SHP2 inhibitor program, including RMC-4630, is the focus of an exclusive global research, development and commercialization agreement with Sanofi.
  • Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 [email protected] For Media: Vida Strategic Partners Tim Brons 415-675-7402 [email protected]